BioPharmSignal logoBioPharmSignal

Biotech News

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsEarnings

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6

Open original release

Related news

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-05-21 21:01 EST

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

GERNGeron2026-05-06 11:00 EST

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

ARGXArgenx2026-07-23 05:00 EST

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

KURAKura Oncology2026-05-12 20:02 EST

Kura Oncology Reports First Quarter 2026 Financial Results

ARGXArgenx2026-05-07 05:00 EST

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

View all latest news

Syndax Pharmaceuticals

Syndax Pharmaceuticals is an oncology company with programs in hematology and solid tumors, including targeted therapies and commercial assets. Its story blends launch execution with pipeline expansion.

Recent company news

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-06-01 11:00 EST

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

SNDXSyndax Pharmaceuticals2026-05-21 21:01 EST

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-05-20 11:00 EST

Syndax Announces Participation in Upcoming Investor Conferences

Stock data

Close
20.52 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States